[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.184.210. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1965

Low Molecular Weight Dextran in Treatment of Severe Ischemia

Author Affiliations

CHICAGO
From the Department of Surgery, Northwestern University School of Medicine and the Veterans Administration Research Hospital, 303 E Chicago Ave, Chicago 60611.

Arch Surg. 1965;91(2):338-341. doi:10.1001/archsurg.1965.01320140128021
Abstract

The flow of blood through the microvasculature is as vital to life as that through the heart and great vessels.

Roe Wells, Jr.

SWEDISH dextran with its molecular weight of 40,000 has been in wide use in situations of easing blood flow. Its properties are quite different from those of its American (weight, 75,000) and British (weight, 150,000) relatives. Principally, it affects a reversal of red cell aggregation and reduces blood viscosity.1 Since this results in an increase in tissue perfusion, it has been apparent that theoretically this agent would be useful in treatment of patients with severe ischemia. Several preliminary reports have suggested some improvement of blood flow by dextran in some ischemic states.2-4 In others, the nontoxic properties and general safety of the agents has been documented.5,6 As a result, it has seen extensive use abroad and in this country in a remarkably diverse group

First Page Preview View Large
First page PDF preview
First page PDF preview
×